|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||11.11 / 28.50|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Conference call today at 4:30 p.m. ET
I'll be watching for entry points to develop this afternoon.
The best way to deal with the struggling market is selective stock picking and good defense.
Here's what you need to know for Friday, March 2.
I think we'll probably see some shifting in the tariff policy over the weekend, giving the market some relief.
Study to evaluate Peptelligence®-Engineered Oral CR845 (CR845/difelikefalin) in Chronic Liver Disease Patients
It is very easy to force trades in this sort of environment.
Data to inform dose selection for planned Phase 2 trial in CLD-associated pruritus
If we have a little consolidating action here the buyers will start pushing again.
There are signs of stabilization, but the market is still digesting some very big swings.
The big question right now is to what degree should you be looking to take positions in individual stocks you may like.
These names are displaying bullish and bearish reversal patters over the last week.
Investors eyeing a purchase of Cara Therapeutics Inc shares, but cautious about paying the going market price of $12.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $7.50 strike, which has a bid at the time of this writing of 95 cents.
Jim Cramer is bullish on Cara Therapeutics, Thomson Reuters, Wynn Resorts, and Edison International.
It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 1,149,738 share decrease in total short interest for Cara Therapeutics Inc , to 7,361,067, a decrease of 13.51% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Management to host conference call today at 4:30 p.m. ET
Trial to evaluate pharmacokinetics and safety of three tablet strengths of Oral CR845
Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)
Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.